<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217269</url>
  </required_header>
  <id_info>
    <org_study_id>IP060</org_study_id>
    <nct_id>NCT00217269</nct_id>
  </id_info>
  <brief_title>The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions</brief_title>
  <acronym>ENDEAVOR IV</acronym>
  <official_title>A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor&#xD;
      Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary&#xD;
      Stent System for the treatment of single de novo lesions in native coronary arteries with a&#xD;
      reference vessel diameter (RVD) of 2.5-3.5 mm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ENDEAVOR IV Trial is a prospective, multi-center, randomized, two-arm, single-blind trial&#xD;
      that will enroll a total of 1,548 patients at up to 80 sites in the US. The ENDEAVOR IV Trial&#xD;
      will assess if the Endeavor stent is equivalent in safety and efficacy to the Taxus stent for&#xD;
      the treatment of single de novo lesions in native coronary arteries with a RVD of 2.5-3.5 mm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure (TVF) rate</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic parameters (in-stent and in-segment) including: percent diameter stenosis (%DS)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss (in-segment late lumen loss is a powered secondary endpoint)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss index</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis (ABR) rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum luminal diameter (MLD)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event (MACE) rate</measure>
    <time_frame>30 days, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal hyperplastic volume and percent volume obstruction (%VO) as measured by intravascular ultrasound (IVUS)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target site revascularization (TSR) rate and clinically-driven TSR rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate and clinically-driven TVR rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1548</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endeavor Drug Eluting Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxus Drug Eluting Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary Artery Stenting</intervention_name>
    <description>Endeavor Drug eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary Artery Stenting</intervention_name>
    <description>Taxus Drug Eluting Stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has clinical evidence of ischemic heart disease, stable or unstable&#xD;
             angina, silent ischemia, or a positive functional study.&#xD;
&#xD;
          -  The patient is an acceptable candidate for percutaneous transluminal coronary&#xD;
             angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test within 7&#xD;
             days before the procedure.&#xD;
&#xD;
          -  The patient or patient's legal representative has been informed of the nature of the&#xD;
             study and agrees to its provisions and has provided written informed consent as&#xD;
             approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective&#xD;
             clinical site.&#xD;
&#xD;
          -  The patient agrees to return to the same research facility for all required&#xD;
             post-procedure follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,&#xD;
             ticlopidine or clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings&#xD;
             (e.g., Phosphorylcholine or Translute), or a sensitivity to contrast media, which&#xD;
             cannot be adequately pre-medicated.&#xD;
&#xD;
          -  History of an allergic reaction or significant sensitivity to drugs such as ABT-578,&#xD;
             rapamycin, tacrolimus, everolimus, or any other analogue or derivative.&#xD;
&#xD;
          -  History of an allergic reaction or significant sensitivity to paclitaxel or drugs in&#xD;
             similar class.&#xD;
&#xD;
          -  A platelet count &lt; 100,000 cells/mm³ or &gt; 700,000 cells/mm³, or a white blood cell&#xD;
             (WBC) count &lt; 3,000 cells/mm³.&#xD;
&#xD;
          -  A serum creatinine level &gt; 2.0 mg/dl within seven days prior to index procedure.&#xD;
&#xD;
          -  Evidence of an acute MI within 72 hours of the intended index procedure (defined as:&#xD;
             QWMI or non-Q wave myocardial infarction (NQWMI) having CK enzymes &gt; 2X the upper&#xD;
             laboratory normal with the presence of a CK-MB elevated above the Institution's upper&#xD;
             limit of normal).&#xD;
&#xD;
          -  Previous PCI of the target vessel within 9 months pre-procedure.&#xD;
&#xD;
          -  Planned PCI of any vessel within 30 days post-procedure.&#xD;
&#xD;
          -  During the index procedure, the target lesion requires treatment with a device other&#xD;
             than PTCA prior to stent placement (including but not limited to, cutting balloon, any&#xD;
             atherectomy, any laser, thrombectomy, etc.).&#xD;
&#xD;
          -  History of a stroke or transient ischemic attack (TIA) within the prior 6 months.&#xD;
&#xD;
          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
          -  Concurrent medical condition with a life expectancy of less than 12 months.&#xD;
&#xD;
          -  Any previous or planned treatment of the target vessel with anti-restenotic therapies&#xD;
             including, but not limited to brachytherapy.&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints; or requires coronary angiography, IVUS or other coronary artery&#xD;
             imaging procedures.&#xD;
&#xD;
          -  Documented left ventricular ejection fraction (LVEF) &lt; 30% at most recent evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B. Leon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University College of Physicians &amp; Surgeons</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

